Optimizing treatment for patients with breast cancer

Seminars in Oncology

Volumn 31, Issue SUPPL. 10, 2004, Pages 4-5

  Cameron, David ^a   Bell, Richard ^b  

^a WESTERN GENERAL HOSPITAL   (United Kingdom)

^b Andrew Love Cancer Centre   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; THYMIDINE PHOSPHORYLASE; TRASTUZUMAB;

ALOPECIA; BONE MARROW SUPPRESSION; BREAST CARCINOMA; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CONFERENCE PAPER; DRUG SAFETY; GENE OVEREXPRESSION; HUMAN; METASTASIS INHIBITION; MONOTHERAPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; TARGET CELL DESTRUCTION;

EID: 5644288564     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2004.07.015     Document Type: Conference Paper

References (14)

1. D.J. Slamon, G.M. Clark, S.G. Wong Human breast cancer correlation of relapse and survival with amplification of the HER-2/neu oncogene Science 235 1987 177 182
2. D.J. Slamon, W. Godolphin, L.A. Jones Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer Science 244 1989 707 712
3. C.L. Vogel, M.A. Cobleigh, D. Tripathy Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer J Clin Oncol 20 2002 719 726
4. D.J. Slamon, B. Leyland-Jones, S. Shak Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 2001 783 792
5. J.M. Extra, F. Cognetti, D. Maraninchi Trastuzumab (Herceptin) plus docetaxel versus docetaxel alone as first-line treatment of HER2-positive metastatic breast cancer (MBC) results of a randomised multicentre trial [abstract 2390] Eur J Cancer 2 suppl 3 2004 125
6. M. Miwa, M. Ura, M. Nishida Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue Eur J Cancer 34 1998 1274 1281
7. J. Schüller, J. Cassidy, E. Dumont Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients Cancer Chemother Pharmacol 45 2000 291 297
8. J. Blum, S. Jones, A. Buzdar Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer J Clin Oncol 17 1999 485 493
9. J. Blum, V. Dieras, P. Lo Russo Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients Cancer 92 2001 1759 1768
10. P. Reichardt, G. Von Minckwitz, P.C. Thuss-Patience Multicenter phase II study of oral capecitabine (Xeloda) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy Ann Oncol 14 2003 1227 1233
11. P. Fumoleau, R. Largillier, C. Clippe Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer Eur J Cancer 40 2004 536 542
12. J. O'Shaughnessy, J. Blum, V. Moiseyenko Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer Ann Oncol 12 2001 1247 1254
13. D. Talbot, V. Moiseyenko, S. Van Belle Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines Br J Cancer 86 2002 1367 1372
14. J. O'Shaughnessy, D. Miles, S. Vukelja Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer phase III trial results J Clin Oncol 20 2002 2812 2823